A new IARC live webinar on evidence in primary cancer prevention By Ogkologos - November 11, 2021 420 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... September 26, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... November 17, 2023 Dealing With Fears March 24, 2021 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 Load more HOT NEWS Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals...
